1.Analysis of CIP2 A expression and prognosis in non-small cell lung cancer patients
Chinese Journal of Biochemical Pharmaceutics 2014;37(4):81-84
Objective To study the different expressions of cancerous inhibitor of protein phosphatase 2A (CIP2A)in non-small cell lung cancer (NSCLC),investigate its clinical significance and potential prognostic value.Methods Immunohistochemical and real-time polymerase chain reaction (PCR)were used to detect the expressions of CIP2A mRNA and protein in two groups of sixty paired NSCLC specimens and adjacent non-cancer tissues.The relationship between its expression and clinical pathological data and prognostic factors were analysed. Results The expression of CIP2A mRNA in NSCLC specimens was higher than those in adjacent non-cancer tissues(P<0.01 );The expression of CIP2A protein in NSCLC tissues was significantly higher than that in the corresponding adjacent non-cancer tissues (P<0.01 ).The expression of CIP2A was closely correlated with the differentiation and lymph node metastasis of NSCLC tissues (P<0.05 ),while incorrelated with sex,age,pathematology type,tumor size and tumor node metastasis (TNM)stage.Conclusion CIP2A highly expresses in NSCLC,and the expression of CIP2A will increase with the differentiation and lymph node metastasis of NSCLC tissues.The expression of CIP2A and lymph node metastasis can be used as an independent risk factor for the prognosis of patients with NSCLC.
2.Correlation between the expression of BAG-1, p53 and platinum-based chemotherapeutic sensitivity in NSCLC
Qian WU ; Zhitu ZHU ; Minwen HA
Cancer Research and Clinic 2009;21(1):23-25,28
Objective To detect the expression of BAG-1 and p53 in postoperative patients paraffin section of non-snmll cell lung cancer (NSCLC), and retrospectively analyze the relationships of clinical feature and platinum-based chemotherapeutic sensitivity in NSCLC, to further investigate the resistance mechanism of platinum. Methods The expression of BAG-1 and p53 was measured by immunohistochemistry in paraffin sections of 125 NSCLC postoperative patients. The existence and prognosis were analyzed after follow-up. Results BAG-1 and p53 showed high expression in NSCLC (positive rate 64.8 %, 46.7 %); BAG-1 positive or p53 negative expression had survival advantage(P<0.05); The group of BAG-1, p53 negative expression could benefit from platinum-based chemotherapy (P<0.05). Conclusion Expressions of BAG-1, p53 correlates with platinum-based chemotherapeutic sensitivity, and maybe become new types of clinical prognostic indicators and contribute to individualized treatment options for NSCLC.
3.Expression of BUB1 and APC protein in different breast tissues and its clinical signifi cance
Yahong WANG ; Xinghua SUN ; Zhitu ZHU ; Minwen HA
China Oncology 2006;0(12):-
Background and purpose:The development of breast cancer is a multi-step process associated with changes in host chromosome,and some of which correlate with the appearance and progression of the tumor. We studied the expression of BUBl,APC protein in normal breast,hyperplasia of mammary glands and breast cancer tissues and evaluated its difference and clinical significance. Methods:The inmmunohistochemical method was used to analyze the expression of BUB1 and APC protein in normal breast,hyperplasia of mammary glands and breast cancer tissues. Results:The positive rate of BUB1 protein expression in normal,hyperplasia of mammary glands and breast cancer tissues was 86.7%,80.0% and46.0%,respectively.There were signifi cant differences among the three breast tissues(P
4.Effect of 5-Aza-CdR on pancreatic carcinoma Capan-2 cell proliferation and PCDH8 gene expression
Yinchun WANG ; Minwen HA ; Yan WANG ; Wei LIU ; Man LI
Chinese Journal of Biochemical Pharmaceutics 2014;(3):16-18
Objective To discuss the effect of 5-Aza-CdR on pancreatic carcinoma Capan-2 cell proliferation and PCDH8 gene expression.Methods Pancreatic carcinoma Capan-2 cells were treated with different doses of 5-Aza-CdR with or without gemcitabine,negative control group without drug,0.08μmol/L group with 0.08μmol/L 5-Aza-CdR,0.40 μmol/L group with 0.40 μmol/L 5-Aza-CdR,2.00 μmol/L group with 2.00 μmol/L 5-Aza-CdR,10 μmol/L group with 10 μmol/L 5-Aza-CdR,50 μmol/L group with 50 μmol/L 5-Aza-CdR. The inhibition ratio of Capan-2 cell proliferation were observed by MTT assay and PCDH8 gene and protein expression were detected by RT-PCR and Western blot. Results The inhibition ratio was increased with 5-Aza-CdR dose increasing(P<0.01),but decreased apparently with times extending(P<0.01). Inhibition ratio in 5-Aza-CdR and gemcitabine group was higher than those with only 5-Aza-CdR or gemcitabine groups(P<0.05 or P<0.01).The levels of PCDH8 gene and protein expression were increased significantly in 5-Aza-CdR treatment groups,with dose dependent (P <0.01 ).Conclusion 5-Aza-CdR can inhibit the proliferation of pancreatic carcinoma Capan-2 cell proliferation,and increase PCDH8 gene expression. The inhibition effect is strong when combined with gemcitabine.
5.Clinical Observation on Treatment of Malignant Hydrothorax with Locally Administered Highly Agglutinative Staphylococcin and Cisplatin
Jian CHENG ; Yuzhi AN ; Xin ZHANG ; Yadi WANG ; Wei LIU ; Yue WANG ; Minwen HA
China Pharmacy 2001;0(12):-
OBJECTIVE: To observe the clinical efficacy of highly agglutinative staphylococcin (HAS) combined with cisplatin in the treatment of malignant hydrothorax after straining and inserting central venous catheter in thoracic cavity. METHODS: 90 patients with malignant hydrothorax combined with lung cancer were randomly divided into A、B、C 3 groups. Central venous catheter was inserted in thoracic cavity for strainage. Group A were intrapleural injected with 5 000 U HAS, group B 40 mg?m-2 cisplatin and group C 5 000 U HAS combined with 40 mg?m-2 cisplatin once a week. Clinical efficacies of 3 groups were evaluated after 3 weeks of treatment. RESULTS: The total effective rate of group A, B and C were 43.0%, 46.7% and 80.0% respectively. There was obvious difference between group C and A as well as group B(P